Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) major shareholder Ltd Nirland sold 1,368,991 shares of the business’s stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $0.10, for a total value of $136,899.10. Following the transaction, the insider now owns 7,031,009 shares of the company’s stock, valued at approximately $703,100.90. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Ltd Nirland also recently made the following trade(s):
- On Monday, October 7th, Ltd Nirland sold 939,009 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $93,900.90.
- On Wednesday, October 2nd, Ltd Nirland sold 333,177 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.10, for a total value of $33,317.70.
- On Monday, September 30th, Ltd Nirland sold 1,016,823 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.12, for a total value of $122,018.76.
Conduit Pharmaceuticals Stock Performance
Shares of CDT stock opened at $0.11 on Wednesday. Conduit Pharmaceuticals Inc. has a one year low of $0.10 and a one year high of $7.83. The firm’s 50 day moving average price is $0.15 and its 200-day moving average price is $1.51.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.
Check Out Our Latest Analysis on CDT
About Conduit Pharmaceuticals
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Stories
- Five stocks we like better than Conduit Pharmaceuticals
- How to Plot Fibonacci Price Inflection Levels
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Technology Stocks Explained: Here’s What to Know About Tech
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.